During the past decade, Donald S. Marks M.D., P.C. conducted 15 clinical trials. In the 10-year time frame, 15 clinical trials started and 5 clinical trials were completed, i.e. on average, 33.3% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 4 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Donald S. Marks M.D., P.C." #1 sponsor was "Eli Lilly and Company" with 5 trials, followed by "Biogen" with 4 trials sponsored, "JANSSEN Alzheimer Immunotherapy Research & Development, LLC" with 3 trials sponsored, "Eisai Inc." with 2 trials sponsored and "University of Southern California" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Donald S. Marks M.D., P.C." #1 collaborator was "National Institute on Aging (NIA)" with 4 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "Alzheimer's Clinical Trials Consortium" with 2 trials as a collaborator, "Alzheimer's Therapeutic Research Institute" with 2 trials as a collaborator and "Biogen" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Donald S. Marks M.D., P.C." are "Alzheimer's Disease" (9 trials), "Alzheimer Disease" (5 trials), "Early Alzheimer's Disease" (2 trials), "Mild Cognitive Impairment" (2 trials) and "Preclinical Alzheimer's Disease" (2 trials). Many other conditions were trialed in "Donald S. Marks M.D., P.C." in a lesser frequency.

Most popular intervention types in "Donald S. Marks M.D., P.C." are "Drug" (17 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (10 trials), "Aducanumab" (3 trials), "Donanemab" (3 trials), "Bapineuzumab 0.5 mg/kg" (2 trials) and "Bapineuzumab 1.0 m/kg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Donald S. Marks M.D., P.C." are 18 trials for "All" genders.

Currently, there are NaN active trials in "Donald S. Marks M.D., P.C.". undefined are not yet recruiting, 4 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Donald S. Marks M.D., P.C., undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Donald S. Marks M.D., P.C., 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".